- Have over 45 years of combined drug discovery and development experiences
- Have successfully progressed over 20 compounds into clinical trials, including an FDA-approved cancer drug
Wentao Zhang, Ph.D.
Founder & President
Wentao has over 15 years of industry experience in drug discovery and preclinical development. He has evaluated over 200 drug targets and helped progress over 20 compounds from discovery to clinical development, including candidates in phase 2 and 3 clinical trials and Cometriq™, a kinase inhibitor approved for medullary thyroid cancer by the FDA. Prior to founding Quintara Discovery in 2012, Wentao was Senior Director of New Lead Discovery at Exelixis, managing key drug discovery platforms and functions that include compound collection, lead discovery and optimization, and in vitro ADME. Wentao is an ad hoc member of the NIH study section on assay development & HTS, and served as President of Chinese American Biopharmaceutical Society 2012-13. He has authored and co-authored discovery data package (biology) and preclinical DMPK study reports for IND and NDA filings, as well as 30 scientific publications. Wentao obtained his Ph.D. degree from University of Wisconsin-Madision, and did post-doctoral research at University of California-Berkeley.
Sean Xiang Wu, Ph.D.
Co-Founder & Head of Discovery Services
Sean has extensive experience in drug discovery and most recently was Associate Director at Exelixis, leading a team of scientists for ADME profiling of all discovery and development compounds. Sean is extremely versatile in optimizing various ADME assays to improve data quality and reproducibility, and utilizing automation in liquid handling and data analysis to improve assay throughput. At Exelixis, he represented and provided DMPK guidance in over 10 cross-functional project teams, including all ADME support for Cometriq™. He is an editorial board member of Journal of Biomolecular Screening. Sean obtained his Ph.D. degree from Georgia Health Sciences University, and did post-doctoral research at Yale University and Novartis Pharmaceuticals.
Julie Ren, Ph.D.
Co-Founder & Head of Bioanalysis and Preclinical Development
Julie has over 14 years of industry experience in drug discovery and development, most recently as Director, Bioanalytical, Nonclinical Development (DMPK) in Exelixis. Julie led the discovery bioanalysis and pharmacokinetics, conducting and managing pharmacokinetics, toxicokinetics, PK/PD, PK/efficacy, drug distribution, metabolite identification, cellular uptake evaluations for lead validation and optimization at Exelixis. She also established and managed the GLP bioanalytical laboratory in supporting non-clinical toxicokinetics, clinical pharmacokinectics, metabolism, drug-drug interaction and bioequivalence studies for over twenty IND and one NDA filings. Julie has participated in multiple successful FDA audits. Julie obtained her Ph.D. from University of Alabama and did post-doctoral research at University of California, San Francisco.